Drugs

Articles

• disulfiram
  20 October 2003

  Microscopical synopsis
  pseudo-Lafora bodies in liver (#6307616#)

• cyanamide
  20 October 2003

  Microscopical synopsis
  pseudo-Lafora bodies in liver (#6307616#)

• 5-FU
  12 March 2004

  5-fluoro-2’-deoxyuridine, 5-fluorouracil, fluorouracil

• ACEIs
  22 November 2004

  angiotensin-converting enzyme inhibitors

• NSAIDs
  22 November 2004

  Non-steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory agents (NSAIAs)

• mycophenolate
  15 December 2003

  MMF, mycophenolate mofetil

• amiodarone
  24 February 2005

  Definition: Amiodarone is a potent antiarrhythmic agent.
  Images
  Amiodarone-induced change in thyroid
  https://twitter.com/aakasharmand/status/727148670987149312
  cirrhosis and amiodarone
  https://twitter.com/CArnold_GI/status/735956508492615682
  Liver injury
  Amiodarone causes elevated liver enzymes in up to 30% of patients and steatohepatitis in 1–2% of patients.
  The majority of cases display liver enzyme abnormalities within 24 h of intravenous infusion.
  Even low oral dosing (200 (...)

• crizotinib
  10 June 2010

  Pfizer drug crizotinibPF-02341066 or 1066, PF-02341066, Xalkori Wikipedia
  Molecular target: ALK
  Definition: Crizotinib is an ALK inhibitor , ROS1 inhibitor and MET inhibitor .
  Crizotinib is undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, advanced non-small cell lung carcinoma (NSCLC ).
  Crizotinib is an oral ALK (anaplastic lymphoma kinase) inhibitor under study in patients with advanced NSCLC carrying the echinoderm (...)

• statins
  9 May 2005

  Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for cholesterol biosynthesis, and are beneficial in the primary and secondary prevention of cardiovascular disease. Most of the benefits of statin therapy are owing to the lowering of serum cholesterol levels.
  However, by inhibiting HMG-CoA reductase, statins can also inhibit the synthesis of isoprenoids, which are important lipid attachments for intracellular signaling molecules, such (...)

• bleomycin
  8 February 2005

  Pathology
  bleomycin-induced pneumopathy
  bleomycin-induced scleroderma
  References
  Chen J, Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer. 2005 Feb;5(2):102-12. PMID: #15685195#

0 | 10 | 20 | 30